Results 161 to 170 of about 179,501 (256)

AI Applications Integrating Legal and Regulatory Perspectives in Mental Health: Systematic Review. [PDF]

open access: yesJMIR AI
Kandeel ME   +7 more
europepmc   +1 more source

‘Shelter is a Dignity’: Rental Racism, Stress and Housing (In)justice

open access: yesAustralian Journal of Social Issues, EarlyView.
ABSTRACT Australia's private rental sector is in crisis, and culturally and racially minoritised renters face compounded harms through both covert and everyday direct forms of rental racism. Drawing on five community‐based focus groups in Melbourne (n = 37), the paper explores how racism manifests across the rental pathway and how it structures the ...
Erika Martino   +3 more
wiley   +1 more source

Intensified Manufactured Non‐Belonging: Working Holiday Makers in Australia During the COVID‐19 Pandemic

open access: yesAustralian Journal of Social Issues, EarlyView.
ABSTRACT Nations manufacture non‐belonging of temporary migrants through policy frameworks that produce exclusion. This precarity maximises the economic benefit of temporary migrant labour by minimising their political, social and legal rights. In this paper, we examine how non‐belonging targeting Working Holiday Makers (WHMs) is manufactured in ...
Donna James, Alanna Kamp
wiley   +1 more source

A new Patient‐Reported Outcome Scale to assess autoimmune Encephalitis: PROSE

open access: yesAnnals of Neurology, EarlyView.
Objective Autoimmune encephalitis (AIE) has long‐lasting effects. Generic clinical assessment‐scales insufficiently capture disease‐specific sequelae. Patient‐reported outcome measures (PROMs) assess outcomes important to patients, ensuring relevance in the clinic and trials.
Juliette Brenner   +24 more
wiley   +1 more source

Barriers and facilitators to healthcare access among Sub-Saharan African migrants in Europe: A scoping review. [PDF]

open access: yesPLoS One
Cynthia AN   +5 more
europepmc   +1 more source

Blood SOD1 Activity in ALS Patients Receiving Tofersen Treatment

open access: yesAnnals of Neurology, EarlyView.
Objective The antisense oligonucleotide tofersen is the first disease‐modifying drug for SOD1‐related amyotrophic lateral sclerosis (ALS) and was approved because of its ability to reduce SOD1 protein and neurofilament levels. The effect of tofersen on SOD1 activity is unclear but of clinical relevance because homozygous SOD1 mutations, linked to ...
Katharina Goehring   +18 more
wiley   +1 more source

Home - About - Disclaimer - Privacy